Quoin Pharmaceuticals (QNRX) Total Debt (2020 - 2023)

Quoin Pharmaceuticals (QNRX) posted Total Debt of $4.0 million for Q1 2023, down 47.38% sequentially from $7.6 million in Q4 2022.

Quoin Pharmaceuticals (QNRX) Total Debt (2020 - 2023) Analysis & Trends

Quoin Pharmaceuticals has reported Total Debt for 4 years, with the latest figure at $4.0 million in Q1 2023.

Quarterly Total Debt changed N/A year-over-year to $4.0 million in Q1 2023, while the trailing twelve-month figure through Mar 2023 was $4.0 million (changed N/A YoY) and the FY2022 annual result came in at $7.6 million, up 61.89% from the prior year.
Total Debt eased to $4.0 million in Q1 2023 per QNRX's latest filing, from $7.6 million in the prior quarter.
Over five years, Total Debt peaked at $7.6 million in Q4 2022 and troughed at $4.0 million in Q1 2023.
A 4-year average of $5.2 million and a median of $4.6 million in 2021 frame the typical range for Total Debt.
The sharpest annual moves came in 2021 and 2022: Total Debt decreased 22.59% in 2021, then soared 61.89% in 2022.
Over 4 years, Total Debt stood at $6.1 million in 2020, then fell by 22.59% to $4.7 million in 2021, then jumped by 61.89% to $7.6 million in 2022, then slumped by 47.38% to $4.0 million in 2023.
According to Business Quant data, Total Debt over the past three periods registered $4.0 million, $7.6 million, and $4.3 million for Q1 2023, Q4 2022, and Q3 2022 respectively.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Total Debt (Qtr)
1	Vertex Pharmaceuticals	137.11 Bn	129.26 Bn	2.84 Bn	-
2	Regeneron Pharmaceuticals	84.98 Bn	76.99 Bn	3.93 Bn	1.99 Bn
3	Argenx Se	64.52 Bn	59.33 Bn	1.37 Bn	-
4	Moderna	53.23 Bn	48.09 Bn	52.00 Mn	591.00 Mn
5	BeOne Medicines	41.23 Bn	36.14 Bn	1.53 Bn	1.07 Bn
6	Alnylam Pharmaceuticals	30.65 Bn	27.34 Bn	992.69 Mn	-
7	Insmed	27.15 Bn	25.99 Bn	358.27 Mn	546.77 Mn
8	Royalty Pharma	26.98 Bn	26.14 Bn	-	9.34 Bn
9	BioNTech SE	26.78 Bn	8.39 Bn	668.28 Mn	770.36 Mn
10	Quoin Pharmaceuticals	491,038.58	491,038.58	-	-

Download Data